Where does Medsolve Limited rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Medsolve Limited ranks #26,833 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Medsolve Limited hold?

Medsolve Limited holds 10 US utility patents granted between 2015 and 2024, spanning 2 technology areas.

What is Medsolve Limited's Innovation Score?

Medsolve Limited has an Innovation Score of 35.0 out of 100 (49th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Medsolve Limited focus on?

Medsolve Limited's top technology area is A61B (DIAGNOSIS; SURGERY; Identification) with 9 patents. Grants appear in 2 CPC subclasses total.

Is Medsolve Limited's patent grant rate increasing or decreasing?

Medsolve Limited's recent grant velocity is +50% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Medsolve Limited's patents?

Medsolve Limited's patents average 27.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Medsolve Limited patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Medsolve Limited

USPTO PatentsView assignee record - 10 granted patents across 2 technology areas, recorded in grant years 2015–2024. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61B (DIAGNOSIS; SURGERY; Identification).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Medsolve ranks #26,833 of 49,997 tracked US assignees by granted-patent volume, with 10 patents across 2 technology areas.

#26,833
of 49,997 US assignees by volume: 49th percentile
by Innovation Score (35.0/100): 27.9
avg claims per patent: +50%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R26833 · Foreign Corporation #26,833 · 10 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-DENSE · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-MICRO 10 grants
MID-PACK #26,833/49,997
PHOTO-FINISH Meat & Livestock…
CPC-NARROW A61B · 2 areas
INNOV-THIN 35.0/100
CLAIMS-DENSE 27.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +50% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Meat & Livestock Australia Ltd (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
Medsolve · this assignee

35
3D Lighting… · lowest

7

What this shows Medsolve's Innovation Score is 35.0/100 (49th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Medsolve's grants concentrate

Medsolve Limited is a focused PatentsView assignee: 2 CPC subclasses with 90% of grants classified under A61B (DIAGNOSIS; SURGERY; Identification). Peak complete grant year is 2017 (2 grants) versus a trough of 1 in 2015. By volume, Medsolve sits between Meat & Livestock Australia Ltd and Mereo Biopharma 1 Limited.

Medsolve's three-year grant acceleration

Medsolve Limited shows 3 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Meat & Livestock…

10
Mecs

10
Medaxis

10
Media Fast LC

10
Mego Afek AC

10
MEI

10
Mentium

10
Mereo Biopharma 1

10
Medsolve ◀

10

What this shows Medsolve holds 10 patents at rank #26,801, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Medsolve

By rank, the assignees closest to #26,801 in granted patent volume.

Leaders in A61B (Diagnosis)

Other assignees with the most granted patents in Medsolve's primary technology class.

Medsolve's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

35 49th percentile higher than 49% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2024

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Medsolve Limited patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	1	10.0%
2016	1	10.0%
2017	2	20.0%
2020	1	10.0%
2021	2	20.0%
2022	1	10.0%
2024	2	20.0%

Which technologies does Medsolve Limited patent most?

A61B - DIAGNOSIS; SURGERY; Identification 9

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 2

Top 2 of 2 technology areas

Where it ranks

Overall rank by patents

#26,833

of 49,997 tracked assignees

Innovation Score

35.0 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Medsolve Limited's patent record in context - here's where to go next.

Medsolve Limited's lead technology class is A61B (DIAGNOSIS; SURGERY; Identification), 90% of its portfolio - see every assignee active in that class. Explore A61B
Ranked #26,833 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Medsolve Limited against Meat & Livestock Australia Ltd, an assignee filing at a similar volume. Compare portfolios
Innovation Score of 35.0/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.